STOCK TITAN
  1. Home
  2. Sec-filings
  3. PHVS
  4. [Form 3] Pharvaris N.V. Initial Statement of Beneficial Ownership

Pharvaris (PHVS) director discloses sizable stock and option holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Pharvaris N.V. director Johannes Schikan reports his beneficial holdings in the company. He directly holds 395,167 shares of Common Stock, which includes restricted stock units that will settle in common shares.

He also holds several stock options to buy common shares, including 16,500 shares at an exercise price of $28.0000 per share expiring in 2036, 15,000 shares at $16.0500 expiring in 2035, 14,000 shares at $22.3100 expiring in 2034, 21,000 shares at $8.0500 expiring in 2033, 17,500 shares at $18.1400 expiring in 2032, and 35,000 shares at $20.0000 expiring in 2031. A grant of 5,500 restricted stock units from March 3, 2026 is scheduled to vest on March 3, 2027.

Positive

  • None.

Negative

  • None.
Insider Schikan Johannes Gerardus Christiaan Petrus
Role Director
Type Security Shares Price Value
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 16,500 shares (Direct); Common Stock — 395,167 shares (Direct)
Footnotes (1)
  1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027. 100% of the option vest on the 12-month anniversary. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Schikan Johannes Gerardus Christiaan Petrus
(Last)(First)(Middle)
1 CRANBERRY HILL SUITE 400
(Street)
LEXINGTON MASSACHUSETTS 02421
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/17/2026		3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock395,167(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)03/03/2027(2)03/03/2036Common Stock16,500$28D
Stock Option (Right to Buy)03/12/2026(2)03/12/2035Common Stock15,000$16.05D
Stock Option (Right to Buy)04/11/2025(2)04/11/2034Common Stock14,000$22.31D
Stock Option (Right to Buy) (3)04/06/2033Common Stock21,000$8.05D
Stock Option (Right to Buy) (4)04/01/2032Common Stock17,500$18.14D
Stock Option (Right to Buy) (5)02/05/2031Common Stock35,000$20D
Explanation of Responses:
1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.
2. 100% of the option vest on the 12-month anniversary.
3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
5. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
/s/ Marnus Nel, Attorney-in-Fact for Johannes Schikan03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Pharvaris (PHVS) Form 3 filing for Johannes Schikan show?

The Form 3 shows director Johannes Schikan’s current holdings in Pharvaris N.V., including 395,167 shares of Common Stock and multiple stock option awards, giving investors a clear view of his existing equity exposure and potential future share ownership through option exercises and RSU vesting.

How many Pharvaris (PHVS) common shares does Johannes Schikan hold?

Johannes Schikan directly holds 395,167 shares of Pharvaris Common Stock. This figure includes restricted stock units that will settle in common shares, reflecting his total reported non-derivative equity interest as of the Form 3 filing date for this initial ownership report.

What stock options in Pharvaris (PHVS) does Johannes Schikan report?

He reports several stock option grants to buy Pharvaris Common Stock, including 16,500 shares at $28.0000, 15,000 at $16.0500, 14,000 at $22.3100, 21,000 at $8.0500, 17,500 at $18.1400 and 35,000 at $20.0000, expiring between 2031 and 2036.

When do Johannes Schikan’s Pharvaris (PHVS) restricted stock units vest?

A grant of 5,500 restricted stock units to Johannes Schikan, awarded on March 3, 2026, is scheduled to vest in full on March 3, 2027. These RSUs settle in Pharvaris common shares and are counted within his reported non-derivative holdings.

Does the Pharvaris (PHVS) Form 3 show any recent insider buying or selling?

The Form 3 does not report new purchases or sales; it lists existing holdings. All entries are categorized as holdings, detailing Schikan’s current common stock position, outstanding restricted stock units, and unexercised stock options with their exercise prices and expiration dates.